This course will be held at:
The Marriott Residence Inn - Riverplace
2115 S.W. River Parkway, Portland, OR 97201
location map: www.residenceinn.com/pdxri
Pre-registration is required to ensure course materials will be available. If you need to confirm your registration, please email a request to
. Same day registration may be available if space permits.
Download registration form (pdf)
No refunds will be issued for cancellations after February 3, 2007.
OHSU is an equal opportunity, affirmative action institution.
The course is designed for the primary care provider and will review both established and newly emerging strategies for long term protection of renal function in patients with mild-moderate chronic kidney disease (CKD). The course content will include a review of issues that the Primary Care Provider faces in early diagnosis and management of CKD; update on measures for preventing contrast nephropathy; basic science concepts which support the role of aldosterone blockade to reduce oxidative stress and prevent renal/vascular tissue injury in conditions associated with extracellular fluid volume excess (CKD, obesity, heart failure); practical guidelines for safe use of aldosterone blockers in mild-moderate CKD; review of new information and clinical implications of increased risk of new-onset diabetes with selected antihypertensive agents; and an update on diuretic mechanisms of action and their implications for optimum management in CKD patients.
- Apply current guidelines to define/stage chronic kidney disease, to identify important management and patient-education issues appropriate to each stage.
- Apply new new evidence-based guidelines for preventing contrast nephropathy in managing patients with mild-moderate CKD undergoing imaging procedures.
- Understand the pathophysiologic basis for aldosterone-associated renal and cardiovascular tissue injury and its clinical relevance in states associated with extracellular fluid volume excess (heart failure, CKD, obesity, hypertension).
- Understand mechanisms and apply practice guidelines for the safe clinical use of renin/AngII and aldosterone receptor blockers to avoid hyperkalemia and manage reduced GFR.
- Understand and apply in clinical practice new information on increased risk of new-onset diabetes associated with specific classic antihypertensive agents.
- Understand and apply new information on actions of classic diuretic agents and its relevance to managing the CKD patient.